Showing all 3 results
Nelfinavir Tablets
FreeNelfinavir Tablets IP
Each Tablet Contains:
Nelfinavir Mesylate
Eq. to Nelfinavir IP 250 mgUsage: – Prevents human immunodeficiency virus (HIV)
Category: – HIV Anti viral Drugs
Therapeutic category: – Antiviral, Anti HIV
Oseltamivir Tablet
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Hard Gelatin Capsule, packed exclusively in highly secure, moisture-resistant Alu-PVC or Alu-Alu blister strips to ensure the absolute chemical stability of the hygroscopic phosphate salt.
Active Ingredient Strength Primary Clinical Function Oseltamivir Phosphate USP/Ph.Eur. 75 mg (Equivalent to Oseltamivir free base) Global Standard: Target adult dose for rapid treatment and prophylaxis of Influenza A/B. Excipients Pregelatinized Starch / Croscarmellose Sodium / Povidone / Sodium Stearyl Fumarate Diluent / Superdisintegrant (Engineered for immediate gastric capsule rupture and rapid systemic absorption) *Pack Sizes: 1×10 Blisters (Optimized perfectly for the standard 5-day acute treatment regimen of two capsules daily).
Ribavirin Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu or heavy-density PVC/PVDC blister strips to ensure the stability of the active nucleoside analog and protect handlers from exposure.
Active Ingredient Strength Primary Clinical Function Ribavirin USP/Ph.Eur. 200 mg Global Clinical Standard: Base titration unit for precise, weight-based antiviral dosing. Ribavirin USP/Ph.Eur. 400 mg High-dose unit to drastically improve pill-burden compliance in heavy patients. Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Povidone / Magnesium Stearate Diluent / Superdisintegrant / Binder (Engineered for immediate gastric dissolution and rapid systemic absorption) *Pack Sizes: 10×10 Blisters or Bottles of 100 (Optimized specifically for high-dose, weight-based daily regimens requiring 4 to 6 tablets per day).
